
Organicell Regenerative Medicine, Inc.
OTC:OCEL
0.01 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Organicell Regenerative Medicine, Inc. |
Symbool | OCEL |
Munteenheid | USD |
Prijs | 0.007 |
Beurswaarde | 10,051,230 |
Dividendpercentage | 0% |
52-weken bereik | 0.005 - 0.052 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Harry L. Leider FACPE, M.B.A., M.D., MBA |
Website | https://www.organicell.com |
An error occurred while fetching data.
Over Organicell Regenerative Medicine, Inc.
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)